Can Januvia (sitagliptin) and Jardiance (empagliflozin) be used together in patients with type 2 diabetes and inadequate glycemic control, particularly those with pre-existing kidney disease or at risk for hypotension?

Can Januvia and Jardiance Be Used Together?

Yes, Januvia (sitagliptin) and Jardiance (empagliflozin) can be used together, and this combination is supported by clinical trial evidence showing superior glycemic control compared to either agent alone, with a well-tolerated safety profile. 1

Evidence Supporting Combination Therapy

The combination of a DPP-4 inhibitor (like Januvia) with an SGLT2 inhibitor (like Jardiance) has been directly studied in clinical trials:

• A 52-week randomized controlled trial demonstrated that empagliflozin 25 mg combined with linagliptin 5 mg (another DPP-4 inhibitor in the same class as Januvia) reduced HbA1c by 1.19% compared to 0.62% with empagliflozin alone and 0.70% with the DPP-4 inhibitor alone when added to metformin. 1

• The combination achieved target HbA1c <7% in 61.8% of patients versus only 32.6% with empagliflozin alone, demonstrating clinically meaningful additive glycemic benefit. 1

• Adverse events were similar across treatment groups (68.6-73.0%), with no hypoglycemic events requiring assistance over 52 weeks. 1

Important Guideline Context: Prioritize Jardiance Over Januvia

While the combination is safe and effective, current 2024 guidelines from the American College of Physicians strongly recommend AGAINST adding DPP-4 inhibitors like Januvia to metformin for reducing morbidity and mortality (strong recommendation, high-certainty evidence). 2

In contrast, guidelines strongly recommend adding SGLT2 inhibitors like Jardiance to metformin to reduce all-cause mortality, major adverse cardiovascular events, chronic kidney disease progression, and heart failure hospitalization (strong recommendation, high-certainty evidence). 2

Practical Algorithm for Decision-Making:

If the patient is already on both medications with good tolerability:

• Continue both agents, as the combination provides superior glycemic control with acceptable safety. 1

If starting new therapy or optimizing regimen:

• Prioritize Jardiance first for its proven mortality and cardiovascular benefits. 2
• Add a GLP-1 receptor agonist (not Januvia) as the second agent if additional glycemic control is needed, as GLP-1 agonists reduce mortality, cardiovascular events, and stroke. 2
• Consider Januvia only if GLP-1 agonists are contraindicated, not tolerated, or cost-prohibitive.

Special Considerations for Kidney Disease

For patients with chronic kidney disease (eGFR ≥30 mL/min/1.73 m²):

• Jardiance is strongly recommended (Grade 1A recommendation) and provides kidney protection, reducing progression of CKD, doubling of serum creatinine by 44%, and need for renal replacement therapy by 55%. 3, 4

• Jardiance reduced incident or worsening nephropathy by 39% in patients with type 2 diabetes and was well-tolerated in those with stage 2 and 3 CKD. 5, 4

• Januvia requires dose adjustment in kidney disease: reduce to 50 mg daily if eGFR 30-45 mL/min/1.73 m², and to 25 mg daily if eGFR <30 mL/min/1.73 m². 6

Safety Monitoring for the Combination

Monitor for SGLT2 inhibitor-specific adverse effects:

• Genital mycotic infections (most common adverse effect): counsel on meticulous genital hygiene and consider topical antifungals for treatment. 7
• Euglycemic diabetic ketoacidosis (rare but serious): educate patients to seek immediate care for nausea, vomiting, or abdominal pain even with normal glucose readings. 7, 8
• Volume depletion and hypotension: assess baseline volume status, especially in elderly patients or those on diuretics. 7

Hypoglycemia risk is low when using this combination without sulfonylureas or insulin, as neither agent depends on insulin secretion for its glucose-lowering effect. 1

Renal function monitoring:

• Check eGFR at baseline and monitor according to CKD stage (annually if eGFR ≥60, every 3-6 months if eGFR 30-59). 9
• Expect a modest initial eGFR decline of 2-4 mL/min with Jardiance—this is hemodynamically mediated and associated with long-term nephroprotection; do not discontinue for this reason alone. 9

Critical Contraindications

Discontinue Jardiance if:

• eGFR falls below 25 mL/min/1.73 m² (for glycemic control purposes). 9
• Patient develops acute kidney injury, severe dehydration, or sepsis. 8
• 3-4 days before scheduled surgery to reduce perioperative ketoacidosis risk. 9

Avoid both agents in:

• Patients with personal or family history of medullary thyroid cancer or MEN2 (this applies to GLP-1 agonists, not relevant here but important if considering alternative agents). 10

Cost and Patient Burden Considerations

Both Januvia and Jardiance are expensive brand-name medications. If cost is a barrier and the patient needs additional therapy beyond metformin, prioritize Jardiance alone over the combination, given its superior mortality and cardiovascular benefits. 2 The incremental glycemic benefit of adding Januvia may not justify the additional cost when weighed against alternatives like GLP-1 agonists that provide both glycemic control and proven cardiovascular/mortality benefits. 2